Dilated cardiomyopathy future or investigational therapies
Dilated cardiomyopathy Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Dilated cardiomyopathy future or investigational therapies On the Web |
American Roentgen Ray Society Images of Dilated cardiomyopathy future or investigational therapies |
FDA on Dilated cardiomyopathy future or investigational therapies |
CDC on Dilated cardiomyopathy future or investigational therapies |
Dilated cardiomyopathy future or investigational therapies in the news |
Blogs on Dilated cardiomyopathy future or investigational therapies |
Risk calculators and risk factors for Dilated cardiomyopathy future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdelrahman Ibrahim Abushouk, MD[2]
Overview
New promising treatments for dilated cardiomyopathy include -among others- stem cell-based treatments, cholesterol-lowering drugs in combination with angiotensin receptor blockers, and protein A immunoadsorption.
Future or Investigational Therapies
There are several new therapies, currently under investigation for dilated cardiomyopathy. The most promising of these therapies include:
- Stem cell-based treatments: Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC])
- Cholesterol lowering drugs as Simvastatin or Rosuvaststin, alone or in combination with angiotensin receptor blockers as valsartan or olmesartan.
- Protein A Immunoadsorption: an extracorporeal technique used for the removal of IgG antibodies and molecules.
- Other drugs under investigation include Qiliqiangxin, Ranolazine, and Benazepril.